Gut microbiota shapes cancer immunotherapy responses
Wanting LeiDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, 610041, Chengdu, Sichuan, ChinaKexun ZhouDivision of Abdominal Cancer, Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, 610041, ChengDu, Sichuan, ChinaYe LeiCollege of Liberal Arts, Neijiang Normal University, 641100, Neijiang, Sichuan, ChinaQiu LiDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, 610041, Chengdu, Sichuan, ChinaHong ZhuDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, 610041, Chengdu, Sichuan, China. [email protected]
2025en
ABI
Abstract
The gut microbiota significantly influences cancer immunotherapy efficacy by modulating immune responses, remodeling the tumor microenvironment (TME), and producing key metabolites. Strategies such as FMT, probiotics, and dietary interventions show promise in enhancing responses to ICIs and ACTs while reducing immune-related adverse events (irAEs). This review summarizes clinical and preclinical findings and discusses microbiota-based interventions and future directions for precision immunotherapy.
Identifiers
Citations and references
Cited by 20 references